Yun Young Ho, Mendoza Tito R, Kang Im Ok, You Chang Hoon, Roh Ju Won, Lee Chang Geol, Lee Won Sup, Lee Keun Seok, Bang Soo-Mee, Park Sang Min, Cleeland Charles S, Wang Xin Shelley
Quality of Cancer Care Branch, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea.
J Pain Symptom Manage. 2006 Apr;31(4):345-52. doi: 10.1016/j.jpainsymman.2005.07.013.
This study aimed to evaluate the Korean version of the M. D. Anderson Symptom Inventory (MDASI-K) as a tool for assessing multiple symptoms in Korean cancer patients. Participants (178 cancer patients and 178 age and sex-matched community-dwelling adults) completed the MDASI-K and the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. The MDASI-K exhibited substantial reliability and validity. Cronbach alpha coefficients were 0.91 and 0.93 in the cancer patients, and 0.96 and 0.96 in the normal group for both symptom and interference, respectively. MDASI-K summary scores correlated significantly with those of the EORTC QLQ-C30. Discriminant validity of the MDASI-K was demonstrated by its ability to clearly distinguish significant differences within different Eastern Cooperative Oncology Group performance statuses and those between the patient and normal groups in the mean scores of both symptom and interference. The MDASI-K is a valid and reliable measure for assessing multiple symptoms in Korean cancer patients.
本研究旨在评估韩国版的安德森症状问卷（MDASI-K）作为评估韩国癌症患者多种症状的工具。参与者（178名癌症患者以及178名年龄和性别匹配的社区居住成年人）完成了MDASI-K以及韩国版的欧洲癌症研究与治疗组织（EORTC）QLQ-C30。MDASI-K表现出了较高的信度和效度。癌症患者症状和干扰项的克朗巴哈α系数分别为0.91和0.93，正常组则分别为0.96和0.96。MDASI-K总分与EORTC QLQ-C30总分显著相关。MDASI-K的判别效度体现在其能够清晰区分不同东部肿瘤协作组体能状态之间以及患者组与正常组在症状和干扰项平均得分上的显著差异。MDASI-K是评估韩国癌症患者多种症状的有效且可靠的工具。
